Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A genomic signature of 254 genes predicting clinical outcome in Primary Cutaneous Melanoma identified

06.04.2006


EORTC Melanoma Group researchers have identified a genomic signature predicting clinical outcome in Primary Cutaneous Melanoma, after patients having undergone standard treatment. The results of the retrospective study are published in today’s issue of the Journal of the National Cancer Institute.

About the study:

The study was initiated on the following observation: Patients with Primary Cutaneous Melanoma having received standard treatment fall into two groups – one group of patients without relapse after four or more years, and another group which recurrently develops metastasis.



Micro-array analysis allowed to isolate a set of 254 genes which are expressed differently in the tumor with good prognosis than in the tumor with bad prognosis. These 254 genes represent a “genomic signature” of the tumor which allows to identify to which of the two groups of prognosis a patient belongs to.

Some of the genes in question have a known activity in melanoma, whereas other genes identified have also been previously shown to be involved in other cancers. Of particular interest are 33 genes in melanomas from patients that did not metastasize – indicating an anti-metastatic role for these genes.

Furthermore, a biological pathway associated with the expression of these genes was identified: Two proteins where shown to intervene in the process of DNA replication. These two proteins (helicasis) represent potential targets for the development of new therapies for the patients that fall within the group with bad prognosis.

The findings allow for a more accurate diagnosis of melanoma and will allow patients to make a more informed choice as to whether or not to take part in clinical trials. For a patient with bad prognosis, taking part in a clinical trial could possibly result in an increase chances of survival or/and quality of life.

The study is the first study that uses a large retrospective series of frozen samples with long-term follow-up to analyze the genes underlying progression in melanoma. Gene expression profiling data is still scarce because of the lack of retrospective collections of frozen tumors.

Nicole Heine | alfa
Further information:
http://www.eortc.be

More articles from Studies and Analyses:

nachricht Some brain tumors may respond to immunotherapy, new study suggests
11.12.2018 | Columbia University Irving Medical Center

nachricht Climate change and air pollution damaging health and causing millions of premature deaths
30.11.2018 | International Institute for Applied Systems Analysis (IIASA)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Data use draining your battery? Tiny device to speed up memory while also saving power

14.12.2018 | Power and Electrical Engineering

Tangled magnetic fields power cosmic particle accelerators

14.12.2018 | Physics and Astronomy

In search of missing worlds, Hubble finds a fast evaporating exoplanet

14.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>